Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple mineral cut the need for powerful blood-pressure drugs in septic shock?

NCT ID NCT07716956

Disease control Sponsor: Alexandria University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This trial investigates whether keeping magnesium levels in the upper normal range can lower the amount and duration of norepinephrine, a drug that raises blood pressure, in adults with septic shock. Participants are randomly assigned to receive individualized magnesium infusions or standard care. Researchers will track total norepinephrine use, ICU stay length, breathing-tube duration, and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
intravenous magnesium sulfate infusions to achieve upper normal serum magnesium levels
What this could lead to
If it works, this could point toward a simple, low-cost way to reduce the amount of blood-pressure medication needed in septic shock, potentially shortening ICU stays.
What could go wrong
This is a small, early-stage trial with only 60 participants, so results may not apply broadly. The intervention may not lower medication needs or improve survival, and magnesium infusions carry risks like low blood pressure or heart rhythm issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female adult patients (aged ≥18 years) diagnosed with septic shock. * Resistant septic shock that requires corticosteroids. Exclusion Criteria: * Pregnancy. * Baseline hypermagnesemia (serum magnesium level \> 2.3 mg/dL). * Renal impairment with creatinine clearance (CrCl) \< 10 ml/min. * Mixed shock.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis Septic shock

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Alexandria Main University Hospital

    Alexandria, Alexandria Governorate, 21526, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.